PGHN enters mid-June with a striking divergence: the stock has shed 21% over the past month, but insiders have responded with an unusually concentrated burst of buying that totals nearly $65 million in net purchases over the past 90 days.
The insider signal is the standout this week. Over just four trading days — June 5 through June 11 — multiple executive committee members and at least two non-executive board members bought shares on the open market, accumulating roughly 22,000 shares at prices between CHF 698 and CHF 724. The single largest transaction on June 5 alone ran to over $10 million. Names are not disclosed under Swiss reporting rules, but the pattern is unmistakable: senior figures are putting real money behind the stock at prices last seen in late 2024. Net purchases across the 90-day window came to 66,725 shares worth approximately $64.9 million — a cluster of conviction buying that is hard to dismiss as routine.
The borrow market tells a calm story, which makes the insider activity more legible as opportunistic rather than defensive. Availability is running at roughly 346% — meaning there are more than three shares available to borrow for every one currently lent out, comfortably within the normal range and well above the 52-week tightest reading of 280%. Borrowing costs are modest at 0.64% annually and have eased around 9% this week, continuing a sharp retreat from a brief spike to 16.6% on May 19 that lasted only a single session before collapsing back to baseline. That spike looks more like a transient technical dislocation than a structural shift in short demand. The ORTEX short score is a middling 48, essentially neutral, and availability has barely moved week-on-week. Short sellers are not driving this story.
The Street picture is more cautious. The consensus price target sits at CHF 986 — a 41% premium to the current CHF 697.8 close — yet the analyst recommendation data shows no recent changes, and the factor scores flag clear headwinds. EPS momentum ranks in just the 9th percentile on a 30-day basis and the 15th on 90 days. Forward earnings revisions are moving the wrong way, with the 12-month forward EPS growth factor scoring only 26 out of 100. The P/E multiple has compressed roughly 3 points over the past month to 13.6x, and the price-to-book ratio has dropped 1.8 turns to 7.2x — both reflecting the sharp de-rating that has pushed the stock to current levels. The dividend score is a bright spot at the 88th percentile, consistent with Partners Group's long track record of growing cash returns, though the most recent dividend data in the system is stale and predates 2023. On valuation, the stock looks cheaper than it has in some time, but the earnings momentum figures suggest the Street has been cutting forecasts rather than upgrading them.
Among close peers, the weekly picture is similarly soft. EQT fell 2.2% on the week, BPT dropped 2.2%, and ICG lost 1.2%. CVC and BAM were exceptions, each rising around 1–2.5%, suggesting the weakness in alternative asset managers is broad but uneven. PGHN's 1.8% weekly decline puts it roughly in line with the softer end of the peer group.
The next formal catalyst is the half-year results scheduled for September 1. Between now and then, the question worth tracking is whether the insider buying cluster — the most concentrated seen in recent quarters — represents a floor-finding moment or merely the first wave of purchases ahead of further estimate cuts.
See the live data behind this article on ORTEX.
Open PGHN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
